Chuan-Ju Liu, PhD
Charles W. Ohse Professor of Orthopaedics & RehabilitationCards
About
Research
Overview
Arthritis is a degenerative disease that affects over 66 million individuals in the United States. It is characterized by the destruction of the extracellular matrix of cartilage and bone, driven by excessive proteolytic activity and an imbalance between inflammatory cytokines and their antagonists. Identifying factors that regulate these processes is essential for understanding disease pathogenesis and developing effective therapies.
At the Liu Lab, we have made significant progress in identifying key regulators of arthritis progression. One of our primary focuses has been on ion channels, particularly sodium channels, and their role in arthritis. We discovered that sodium channel Nav1.7, previously believed to be specific to neurons, is expressed at low levels in chondrocytes but plays a critical role in osteoarthritis progression. Our studies demonstrated that genetic deletion or pharmacological inhibition of Nav1.7 significantly reduces joint damage and alleviates pain in multiple mouse models of osteoarthritis. These findings underscore the therapeutic potential of targeting Nav1.7 for disease-modifying treatments in osteoarthritis.
Beyond ion channel research, we have extensively studied progranulin (PGRN), an autocrine growth factor-like molecule with diverse functions. Originally identified in our lab as both a chondrogenic and osteoarthritis-related growth factor, PGRN was later shown to interact with tumor necrosis factor (TNF) receptors, linking it to inflammation and autoimmunity, particularly inflammatory arthritis. Our ongoing research seeks to further elucidate the role of PGRN in arthritis and autoimmune diseases, with a specific focus on osteoarthritis and rheumatoid arthritis, aiming to develop PGRN-based interventions for inflammatory and degenerative conditions.
Moreover, our investigation into PGRN’s role in lung inflammation led to its unexpected identification as a modifier in Gaucher disease, a common lysosomal storage disorder. This discovery provides a foundation for further studies on PGRN's role in lysosomal storage diseases and neurodegenerative conditions, offering a unique target for therapeutic development in these and potentially related disorders.
Our lab continues to integrate molecular, cellular, and in vivo approaches to address fundamental questions in musculoskeletal and related diseases, with a strong focus on translating our findings into innovative therapeutic strategies.
Medical Research Interests
News
News
- February 12, 2024Source: WTNH
Epilepsy medication could help those with osteoarthritis
- January 21, 2024Source: CT Insider
Yale University study a potential game changer for treating osteoarthritis
- January 19, 2024Source: Medical News Today
An epilepsy drug: A new way to treat osteoarthritis pain?
- January 03, 2024
Breakthrough in Osteoarthritis Research: Nav1.7 Sodium Channels Unveiled as Potential Game-Changer